Payment overview · 2025
General Payments
$1,493.31
72 reported records · 19 companies
Healthcare provider profile · identity verified
Kathy N Chism, MD
Allopathic & Osteopathic Physicians|Family Medicine · POWELL, TN · NPI 1710929484
Verified facts
What the public records show
CMS Open Payments records show Kathy N Chism, MD received $1,493.31 in general payments during 2025 across 72 reported records.
Novo Nordisk Inc accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $283.98 | 19.0% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $199.16 | 13.3% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $185.70 | 12.4% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $139.21 | 9.3% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $104.63 | 7.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $93.45 | 6.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $92.80 | 6.2% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.99 | 5.1% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.18 | 4.5% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.67 | 3.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.51 | 3.4% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.93 | 2.5% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.33 | 1.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.01 | 1.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.38 | 1.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.05 | 1.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.02 | 1.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.20 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.11 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,443.36 | 71 |
| Long term medical supply or device loan | $49.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $185.70 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $180.16 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $135.30 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $112.37 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $104.63 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $103.33 | 1 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $103.33 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $89.26 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $75.99 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.44 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $72.56 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $70.57 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $67.18 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.40 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.71 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $53.71 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $51.67 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $50.51 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $49.95 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $36.99 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 19 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 55 |
| Ezetimibe | Ezetimibe | 194 | 48 |
| Metformin Hcl Er | Metformin Hcl | 164 | 40 |
| Lisinopril | Lisinopril | 160 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 33 |
| Omeprazole | Omeprazole | 141 | 36 |
| Montelukast Sodium | Montelukast Sodium | 134 | 28 |
| Alendronate Sodium | Alendronate Sodium | 111 | 23 |
| Furosemide | Furosemide | 101 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 27 |
| Gabapentin | Gabapentin | 90 | 18 |
| Losartan Potassium | Losartan Potassium | 88 | 23 |
| Simvastatin | Simvastatin | 86 | 26 |
| Potassium Chloride | Potassium Chloride | 85 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 26 |
| Benazepril Hcl | Benazepril Hcl | 77 | 20 |
| Sertraline Hcl | Sertraline Hcl | 77 | 20 |
| Irbesartan | Irbesartan | 69 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 40 |
| Famotidine | Famotidine | 58 | 16 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Metformin Hcl | Metformin Hcl | 53 | 12 |
| Eliquis | Apixaban | 52 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 12 |
| Synthroid | Levothyroxine Sodium | 46 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Allopurinol | Allopurinol | 44 | 12 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 44 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 11 |
| Trazodone Hcl | Trazodone Hcl | 40 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 30 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Atenolol | Atenolol | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 19 |
| Carvedilol | Carvedilol | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Prednisone | Prednisone | 12 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,493.31 · 72 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COMIRNATY, CONTRAVE, ELIQUIS, ENHERTU, FARXIGA, FREESTYLE INSULINX, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Heplisav-B, JARDIANCE, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XYOSTED, ZAVZPRET, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error